Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
70.41
-1.40 (-1.95%)
At close: Mar 28, 2025, 4:00 PM
71.41
+1.00 (1.42%)
After-hours: Mar 28, 2025, 6:49 PM EDT
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 21 analysts with 12-month price forecasts for Sarepta Therapeutics stock have an average target of 164.05, with a low estimate of 75 and a high estimate of 230. The average target predicts an increase of 132.99% from the current stock price of 70.41.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 6 | 6 | 6 | 5 |
| Buy | 12 | 13 | 13 | 13 | 12 | 12 |
| Hold | 2 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 1 | 1 | 2 | 2 | 2 |
| Total | 20 | 22 | 21 | 22 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Hold Maintains $105 → $80 | Hold | Maintains | $105 → $80 | +13.62% | Mar 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $163 | Buy | Reiterates | $163 | +131.50% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $75 | Strong Sell | Reiterates | $75 | +6.52% | Mar 19, 2025 |
| Deutsche Bank | Deutsche Bank | Hold Maintains $124 → $99 | Hold | Maintains | $124 → $99 | +40.61% | Mar 19, 2025 |
| Needham | Needham | Strong Buy Reiterates $202 | Strong Buy | Reiterates | $202 | +186.89% | Mar 18, 2025 |
Financial Forecast
Revenue This Year
3.19B
from 1.90B
Increased by 67.83%
Revenue Next Year
4.01B
from 3.19B
Increased by 25.66%
EPS This Year
8.84
from 2.34
Increased by 278.15%
EPS Next Year
13.88
from 8.84
Increased by 56.96%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.8B | 4.9B | 6.3B | ||
| Avg | 3.2B | 4.0B | 4.4B | ||
| Low | 2.3B | 2.9B | 3.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 100.7% | 53.1% | 57.2% | ||
| Avg | 67.8% | 25.7% | 10.9% | ||
| Low | 19.1% | -9.1% | -23.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.18 | 22.41 | 30.62 | ||
| Avg | 8.84 | 13.88 | 15.78 | ||
| Low | 2.01 | 7.45 | 8.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 549.3% | 153.4% | 120.6% | ||
| Avg | 278.2% | 57.0% | 13.7% | ||
| Low | -14.1% | -15.8% | -37.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.